IBDEI0RS ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13684,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,13685,0)
 ;;=203.01^^83^858^71
 ;;^UTILITY(U,$J,358.3,13685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13685,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,13685,1,5,0)
 ;;=5^  Multiple Myeloma
 ;;^UTILITY(U,$J,358.3,13685,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,13686,0)
 ;;=238.6^^83^858^74
 ;;^UTILITY(U,$J,358.3,13686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13686,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,13686,1,5,0)
 ;;=5^  Plasmacytoma
 ;;^UTILITY(U,$J,358.3,13686,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,13687,0)
 ;;=37.2^1^83^858^33^Other ^1
 ;;^UTILITY(U,$J,358.3,13687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13687,1,4,0)
 ;;=4
 ;;^UTILITY(U,$J,358.3,13687,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,13688,0)
 ;;=175.9^^83^858^36
 ;;^UTILITY(U,$J,358.3,13688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13688,1,4,0)
 ;;=4^175.9
 ;;^UTILITY(U,$J,358.3,13688,1,5,0)
 ;;=5^  Breast (Male)
 ;;^UTILITY(U,$J,358.3,13688,2)
 ;;=^267205
 ;;^UTILITY(U,$J,358.3,13689,0)
 ;;=196.9^^83^858^46
 ;;^UTILITY(U,$J,358.3,13689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13689,1,4,0)
 ;;=4^196.9
 ;;^UTILITY(U,$J,358.3,13689,1,5,0)
 ;;=5^  Lymph Nodes
 ;;^UTILITY(U,$J,358.3,13689,2)
 ;;=^267313
 ;;^UTILITY(U,$J,358.3,13690,0)
 ;;=202.80^^83^858^73
 ;;^UTILITY(U,$J,358.3,13690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13690,1,4,0)
 ;;=4^202.80
 ;;^UTILITY(U,$J,358.3,13690,1,5,0)
 ;;=5^  Non-Hodgkin's Lymphoma
 ;;^UTILITY(U,$J,358.3,13690,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,13691,0)
 ;;=200.00^^83^858^75
 ;;^UTILITY(U,$J,358.3,13691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13691,1,4,0)
 ;;=4^200.00
 ;;^UTILITY(U,$J,358.3,13691,1,5,0)
 ;;=5^  Reticulosarcoma
 ;;^UTILITY(U,$J,358.3,13691,2)
 ;;=^72635
 ;;^UTILITY(U,$J,358.3,13692,0)
 ;;=200.10^^83^858^70
 ;;^UTILITY(U,$J,358.3,13692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13692,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,13692,1,5,0)
 ;;=5^  Lymphosarcoma
 ;;^UTILITY(U,$J,358.3,13692,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,13693,0)
 ;;=204.90^^83^858^68
 ;;^UTILITY(U,$J,358.3,13693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13693,1,4,0)
 ;;=4^204.90
 ;;^UTILITY(U,$J,358.3,13693,1,5,0)
 ;;=5^  Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,13693,2)
 ;;=^267529
 ;;^UTILITY(U,$J,358.3,13694,0)
 ;;=100^1^83^858^66^Myeloma/Lymphoma^1
 ;;^UTILITY(U,$J,358.3,13694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13694,1,4,0)
 ;;=4
 ;;^UTILITY(U,$J,358.3,13694,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,13695,0)
 ;;=205.90^^83^858^72
 ;;^UTILITY(U,$J,358.3,13695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13695,1,4,0)
 ;;=4^205.90
 ;;^UTILITY(U,$J,358.3,13695,1,5,0)
 ;;=5^  Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,13695,2)
 ;;=^267541
 ;;^UTILITY(U,$J,358.3,13696,0)
 ;;=V10.21^^83^858^54
 ;;^UTILITY(U,$J,358.3,13696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13696,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,13696,1,5,0)
 ;;=5^  Larynx
 ;;^UTILITY(U,$J,358.3,13696,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,13697,0)
 ;;=848.9^^83^859^6
 ;;^UTILITY(U,$J,358.3,13697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13697,1,4,0)
 ;;=4^848.9
 ;;^UTILITY(U,$J,358.3,13697,1,5,0)
 ;;=5^Sprain
 ;;^UTILITY(U,$J,358.3,13697,2)
 ;;=^123990
 ;;^UTILITY(U,$J,358.3,13698,0)
 ;;=829.0^^83^859^4
 ;;^UTILITY(U,$J,358.3,13698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13698,1,4,0)
 ;;=4^829.0
 ;;^UTILITY(U,$J,358.3,13698,1,5,0)
 ;;=5^Fracture, Closed
 ;;^UTILITY(U,$J,358.3,13698,2)
 ;;=^48084
 ;;^UTILITY(U,$J,358.3,13699,0)
 ;;=829.1^^83^859^5
 ;;^UTILITY(U,$J,358.3,13699,1,0)
 ;;=^358.31IA^5^2
